Core Insights - Beyond Air, Inc. has established Vanderbilt University Medical Center (VUMC) as its first luminary site to evaluate and promote the clinical and operational benefits of its LungFit® PH device, which utilizes tankless nitric oxide (iNO) technology [1][3] - The collaboration aims to enhance hospital-based nitric oxide therapy and optimize LungFit products through VUMC's advanced research and clinical excellence [2] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to improve patient outcomes in respiratory illnesses, neurological disorders, and solid tumors [5] - The company has received FDA approval and CE Mark for its LungFit PH system, which is designed for treating term and near-term neonates with hypoxic respiratory failure [5] Product Details - LungFit PH generates nitric oxide from room air, eliminating the need for traditional high-pressure cylinders, thus streamlining operations and enhancing efficiency in hospital settings [3][7] - The device can deliver nitric oxide at concentrations ranging from 1 ppm to 80 ppm, with potential applications in treating severe acute lung infections and chronic lung infections [7][8] Strategic Importance - The partnership with VUMC is seen as a significant step for Beyond Air, allowing the company to demonstrate the full utility of its technology to healthcare professionals and potential customers [3] - VUMC's commitment to medical innovation positions it as an ideal partner for Beyond Air in advancing iNO technology and delivery systems [3]

Core Insights - Beyond Oil Ltd. has successfully completed its first order under a five-year distribution agreement with Deep Frying Solutions Pvt Ltd for the Indian market, receiving full payment for an initial shipment of 6 tonnes [1][2][3] - The total estimated contract value for the five-year agreement is approximately $9.58 million USD, which includes the purchase of around 57 containers [2] Company Overview - Beyond Oil Ltd. is a food-tech innovation company focused on reducing health risks associated with fried food, improving sustainability, and lowering operational costs [4] - The company's patented technology significantly reduces harmful compounds in frying oil, addressing health concerns linked to the reuse of frying oil in various food service settings [4] - Beyond Oil's solutions are backed by extensive research highlighting their effectiveness in mitigating health risks, including links to cancer and cardiovascular diseases, while also improving food quality and reducing environmental impact [4]

Company Overview - NeuroNOS is a biopharmaceutical company focused on developing treatments for Autism Spectrum Disorder (ASD) and other neurological conditions, including Alzheimer's disease and brain cancers [2][9] - The company has secured an initial $2 million in equity financing to accelerate the preclinical development of its small-molecule drug designed for children with autism [2][3] Drug Development - The drug under development aims to regulate nitric oxide (NO) levels in the brain, which has shown promise in improving neurological function [2][3][9] - NeuroNOS is currently in advanced stages of formulation development, focusing on a subcutaneous injection with plans for an oral formulation to enhance accessibility for pediatric patients [6][9] Research and Scientific Basis - The research supporting NeuroNOS's drug is based on findings from Prof. Haitham Amal, indicating that children with ASD exhibit elevated NO levels, and inhibiting NO production can reverse autism-like phenotypes in models [3][4] - The partnership with the Hebrew University has validated these findings in over 700 animals and human stem cell-derived neurons, providing biological evidence of NO dysregulation's role in ASD [4][8] Market Context - Autism Spectrum Disorder is a complex neurodevelopmental condition affecting millions globally, with rising prevalence rates intensifying the need for effective treatments [7][8] - Currently, there are no FDA-approved drugs targeting the biological mechanisms underlying ASD, highlighting a critical gap that NeuroNOS aims to address [8]

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has signed its first distribution agreement (the “Agreement”) in Portugal with Serious Formula Ltd (“Serious Formula” or the “Distributor ...

Core Insights - Beyond Air, Inc. has expanded its international distribution network for the LungFit PH system, now covering 18 countries following new agreements in France, Turkey, Romania, and Morocco [1][2] - The company anticipates a rapid commercial ramp-up in international markets, leveraging established distribution partners with medical device infrastructure [2] Distribution Agreements - Recent agreements include partnerships with EUROCARE for France, Medelart Healthcare for Turkey, Abb Neopuls for Romania, and OXYPLUS for Morocco [1][2] - The current distribution partners also include Getz Healthcare across multiple Asian countries, Saudi Health Services CO in Saudi Arabia, and MDC Care Medical Trading in the UAE and surrounding regions [2] Product Overview - LungFit PH is a tankless system that generates nitric oxide (NO) from room air, enhancing operational efficiency and supporting sustainability in hospital settings [3][4] - The device can deliver NO at concentrations ranging from 1 ppm to 80 ppm, with potential applications in treating severe acute lung infections and chronic lung infections [4][5] Regulatory Status - LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand, and New Zealand [6] - The system is designated as a medical device by the U.S. FDA and is intended for use in treating hypoxic respiratory failure in neonates [9] Therapeutic Applications - Nitric oxide plays a critical role in various biological functions and is used in treating conditions such as adult respiratory distress syndrome and persistent pulmonary hypertension [7] - Exogenous inhaled NO is believed to have antimicrobial properties, potentially effective against a range of pathogens, including multi-drug-resistant strains [8]

GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovatio ...

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce that it has signed a distribution agreement (the “Agreement”) with Deep Frying Solutions Pvt Ltd, a newly formed company based in Gujarat, India ( ...

VANCOUVER, B.C. and KIBBUTZ YIFAT, ISRAEL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE: BOIL) (OTCQB: BEOLF) (Frankfurt: UH9) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste, and enhancing sustainability, is pleased to announce its entry into the African market through a new distribution agreement with Minrosolve Proprietary in South Africa. This agreement marks Beyond ...

Core Insights - Beyond Oil Ltd. has successfully delivered its first shipment of proprietary oil treatment products to T&J Oil Pty Ltd. as part of a five-year distribution agreement aimed at expanding into the Australian market [1][2][3] - The initial shipment consisted of 5.4 tonnes of products and is part of a minimum purchase commitment of approximately US$4.9 million [2] - The partnership with T&J Oil is expected to transform the food service industry in Australia by providing healthier and more sustainable frying solutions [3] Company Overview - Beyond Oil Ltd. is a food-tech innovation company focused on reducing health risks associated with fried food while enhancing sustainability and lowering operational costs [1][4] - The company's patented technology has received regulatory clearances from the FDA and Health Canada, significantly reducing harmful compounds in frying oil [4] - Beyond Oil addresses the widespread practice of reusing frying oil, which poses health risks such as links to cancer and cardiovascular diseases, by offering solutions that improve food quality and reduce environmental impact [4]

Financial Performance - Revenues for the fiscal third quarter ended December 31, 2024, were $1.1 million, a 34% increase compared to $0.8 million for the previous quarter ended September 30, 2024[10] - Total revenues for the three months ended December 31, 2024, were $1,072,000, compared to $391,000 for the same period in 2023, representing a 174% increase[27] - Gross loss for the three months ended December 31, 2024, was $(215,000), an improvement from $(356,000) in the same period of 2023[27] - Net loss attributable to Beyond Air, Inc. for the three months ended December 31, 2024, was $(13,032,000), compared to $(16,220,000) for the same period in 2023, showing a 20% improvement[27] - Comprehensive loss attributable to Beyond Air, Inc. for the three months ended December 31, 2024, was $(13,093,000), compared to $(16,229,000) for the same period in 2023, indicating a 19% improvement[27] Expenses - Research and development expenses decreased to $3.0 million for the quarter ended December 31, 2024, down from $6.8 million for the same period in 2023[12] - Selling, general and administrative expenses were $7.7 million for the quarter ended December 31, 2024, a decrease from $9.8 million in the prior year[13] - Research and development expenses for the three months ended December 31, 2024, were $(3,005,000), down from $(6,838,000) in the same period of 2023, indicating a 56% reduction[27] - Selling, general and administrative expenses for the three months ended December 31, 2024, were $(7,732,000), compared to $(9,768,000) in the same period of 2023, reflecting a 21% decrease[27] Cash and Assets - Cash burn for the fiscal quarter ended December 31, 2024, was $7.6 million, excluding financing impacts[14] - As of December 31, 2024, the company reported cash, cash equivalents, and marketable securities of $10.9 million, with total debt outstanding of $11.8 million[15] - Total current assets decreased to $19,344,000 as of December 31, 2024, from $43,936,000 as of March 31, 2024, a decline of 56%[26] - Cash and cash equivalents decreased to $4,601,000 as of December 31, 2024, from $11,378,000 as of March 31, 2024, a decline of 60%[26] - Total liabilities decreased to $15,763,000 as of December 31, 2024, from $29,775,000 as of March 31, 2024, a reduction of 47%[26] Market and Regulatory Developments - The company received CE Mark for LungFit PH in Europe, allowing access to a significant portion of the global market, and anticipates initial commercial shipments in 2025[4] - Six new hospital starts in the U.S. were recorded in the quarter ended December 31, 2024, indicating growing demand for LungFit PH[5] - A $1 million milestone payment was triggered by the CE Mark certification from Getz Healthcare, with double-digit royalty payments expected based on LungFit PH net sales[8] - The company expects to have regulatory approvals in eight countries under the partnership with Getz Healthcare by the end of the calendar year[5] Future Outlook - Topline data from the Phase 1b trial for the NeuroNOS program is anticipated late in calendar 2025 or early 2026[8] - The weighted average number of shares outstanding for the three months ended December 31, 2024, was 88,074,511, compared to 32,462,476 for the same period in 2023[27]